Glaukos (Laguna Hills, California) has priced what analysts of the minimally invasive glaucoma surgical space (MIGS) are calling a very aggressive initial public offering (IPO). The company reported the pricing of 5,358,000 million shares of its common stock at $13 to $15 per share. If successful the company could net more than $75 million from the public offering. At the midpoint of the proposed range, Glaukos would command a fully diluted market value of $474 million.